Real-world treatment of adult patients with Guillain-Barré syndrome over the last two decades.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 09 2021
27 09 2021
Historique:
received:
10
08
2021
accepted:
09
09
2021
entrez:
28
9
2021
pubmed:
29
9
2021
medline:
24
12
2021
Statut:
epublish
Résumé
This study investigated treatment characteristics of Guillain-Barré syndrome (GBS) in a real-world setting between 2000 and 2019. We analyzed clinical improvement between nadir and last follow-up in patients with severe GBS (defined as having a GBS disability scale > 2 at nadir) and aimed to detect clinical factors associated with multiple treatments. We included 121 patients (74 male; median age 48 [IQR 35-60]) with sensorimotor (63%), pure motor (15%), pure sensory (10%) and localized GBS (6%) as well as Miller Fisher syndrome (6%). 44% of patients were severely affected. All but one patient received at least one immunomodulatory treatment with initially either intravenous immunoglobulins (88%), plasma exchange (10%) or corticosteroids (1%), and 25% of patients received more than one treatment. Severe GBS but not age, sex, GBS subtype or date of diagnosis was associated with higher odds to receive more than one treatment (OR 4.22; 95%CI 1.36-13.10; p = 0.01). Receiving multiple treatments had no adjusted effect (OR 1.30, 95%CI 0.31-5.40, p = 0.72) on clinical improvement between nadir and last follow-up in patients with severe GBS. This treatment practice did not change over the last 20 years.
Identifiants
pubmed: 34580356
doi: 10.1038/s41598-021-98501-y
pii: 10.1038/s41598-021-98501-y
pmc: PMC8476500
doi:
Substances chimiques
Adrenal Cortex Hormones
0
Immunoglobulins, Intravenous
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
19170Informations de copyright
© 2021. The Author(s).
Références
Clin Chem. 2017 Dec;63(12):1856-1865
pubmed: 29021324
Lancet. 2021 Mar 27;397(10280):1214-1228
pubmed: 33647239
Ann Neurol. 1997 Mar;41(3):298-306
pubmed: 9066350
Clin Chem Lab Med. 2016 Feb;54(2):285-92
pubmed: 26079822
Brain. 2007 Sep;130(Pt 9):2245-57
pubmed: 17337484
Lancet. 1978 Oct 7;2(8093):750-3
pubmed: 80682
Lancet Neurol. 2007 Jul;6(7):589-94
pubmed: 17537676
Neurology. 2019 Jul 2;93(1):e59-e76
pubmed: 31175208
Cochrane Database Syst Rev. 2016 Oct 24;10:CD001446
pubmed: 27775812
Lancet. 2016 Aug 13;388(10045):717-27
pubmed: 26948435
J Neurol Neurosurg Psychiatry. 2020 Feb;91(2):113-121
pubmed: 31586949
J Neurol Neurosurg Psychiatry. 2015 Jan;86(1):115-9
pubmed: 24816419
Muscle Nerve. 1991 Nov;14(11):1103-9
pubmed: 1745285
Lancet Neurol. 2021 Apr;20(4):275-283
pubmed: 33743237
Cochrane Database Syst Rev. 2017 Feb 27;2:CD001798
pubmed: 28241090
Neurology. 2010 May 25;74(21):1680-6
pubmed: 20427754
Nat Rev Neurol. 2019 Nov;15(11):671-683
pubmed: 31541214
J Clin Neuromuscul Dis. 2016 Sep;18(1):1-11
pubmed: 27552383
Neurology. 2001 Apr 24;56(8):1104-6
pubmed: 11320188
Lancet. 2004 Jan 17;363(9404):192-6
pubmed: 14738791
Cochrane Database Syst Rev. 2014 Sep 19;(9):CD002063
pubmed: 25238327
Brain. 2014 Jan;137(Pt 1):33-43
pubmed: 24163275
J Neurol Neurosurg Psychiatry. 2017 Apr;88(4):346-352
pubmed: 27837102
Cochrane Database Syst Rev. 2007 Jan 24;(1):CD004761
pubmed: 17253522